Asia Pacific
Refine Search
Biotechnology
The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line treatment of adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. 10 July 2025
Biotechnology
BeOne Medicines - the Sino-American oncology specialist formerly known as BeiGene - has announced that the National Institute for Health and Care Excellence (NICE) has recommended Brukinsa (zanubrutinib) to treat relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment. 10 July 2025
Biotechnology
Japanese authorities are putting Eisai under pressure to reconsider the price of its Alzheimer’s disease therapy Leqembi (lecanemab), after a government-backed review found that the drug significantly exceeds accepted cost-effectiveness thresholds in the country. 10 July 2025
Pharmaceutical
Singapore-based market expansion services provider DKSH Business Unit Healthcare announced a partnership with Germany’s Bayer. 10 July 2025
Biotechnology
Japan’s JCR Pharmaceuticals closed 15% higher after Wednesday’s trading, as it signed a new licensing deal. 9 July 2025
Pharmaceutical
Shares in Japanese drugmaker Otsuka Holdings closed nearly 2% lower Tuesday, after disappointing clinical trial results from one of its subsidiaries. 8 July 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 7 July 2025
Pharmaceutical
Chinese biotech Brii Biosciences has licensed its experimental antibiotic BRII-693 to domestic pharma business Joincare Group for development and commercialization in China, as part of a technology transfer and exclusive licensing agreement announced on Wednesday. 4 July 2025
Pharmaceutical
A new company is responsible for Japanese promotional activities for Actair, Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis. 4 July 2025
Pharmaceutical
Multinational pharmaceutical companies (MNCs) are facing significant challenges in China's vaccine market, as regulatory scrutiny, domestic competition, and changing consumer behaviors disrupt a once-thriving sector. 4 July 2025
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended Fruzaqla (fruquintinib) be reimbursed by the National Health Service (NHS), Japanese drug major Takeda’s local subsidiary revealed today. 3 July 2025
Biotechnology
The US Food and Drug Administration has granted accelerated approval to sunvozertinib (trade name Zegfrovy) from Dizal (Jiangsu) Pharmaceutical for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 3 July 2025
Biotechnology
Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese pharmaceutical company, Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates. 2 July 2025
Biotechnology
Taiwanese biotech HanchorBio has signed a licensing agreement with China’s Shanghai Henlius Biotech. 2 July 2025
Pharmaceutical
Mitsubishi Tanabe Pharma Corporation is now under the ownership of US private investment firm Bain Capital Private Equity. 2 July 2025
Biotechnology
Sino-American antibody company Adagene has announced a strategic investment and option exercise by Sanofi. 1 July 2025
Pharmaceutical
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA). 30 June 2025
Pharmaceutical
Japanese drugmaker Shionogi has filed a supplemental application in Japan to broaden the use of its oral antiviral Xocova (ensitrelvir), aiming to include children as young as six who weigh at least 20 kilograms. 30 June 2025
Biotechnology
Australian biotech Dimerix today revealed it has received the first development milestone payment of 400 million yen (~AU$4.2 million; US$2.7 million) from Japan’ FUSO Pharmaceutical, the exclusive licensee of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 30 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical has received marketing authorization in China from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed innovative humanized monoclonal antibody (MAb) tagitanlimab (formerly KL-A167) used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC). 23 January 2025
Biotechnology
Suzhou, China-based Ascentage Pharma revealed that it plans to raise $149 million by offering 7.3 million American Depositary Shares (ADSs) at $20.34, the as-converted January 17 close of its shares on the Hong Kong Stock Exchange. 22 January 2025
Biotechnology
China’s Junshi Biosciences yesterday revealed that its wholly-owned subsidiary TopAlliance Bioscience has entered into a distribution and marketing partnership with Danish dermatology specialist LEO Pharma for toripalimab in Europe. 21 January 2025
Pharmaceutical
Japanese drugmaker Sumitomo Pharma Company has concluded a co-promotion collaboration partner agreement with US healthcare giant Johnson & Johnson. 20 January 2025
Biotechnology
UK pharma major AstraZeneca on Friday revealed that Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the USA. 18 January 2025
Biotechnology
Orna Therapeutics and Shanghai Simnova have announced an expansion of their strategic collaboration to develop RNA-based therapies in multiple myeloma. 17 January 2025
Pharmaceutical
China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC), from Innovent Biologics and Aosaikang Pharmaceuticals (ASK Pharm). 17 January 2025
Pharmaceutical
Japanese firms Veneno Technologies and ASKA Pharmaceutical have entered into a joint research agreement to conduct a drug discovery program to obtain functional disulfide-rich peptides (DRPs) for ion channels selected by the companies. 16 January 2025
Pharmaceutical
Two companies have joined forces to investigate the potential for palbociclib, marketed by Pfizer as Ibrance, to be used as an Alzheimer’s disease drug. 15 January 2025
Biotechnology
Shares of US biotech Regenxbio surged 18.4% in pre-open trading Tuesday after announced a strategic partnership with Japan’s Nippon Shinyaku. 15 January 2025
Biotechnology
Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property rights of the antitumor-associated mucin-1 (TA-MUC1) antibody, gatipotuzumab. 15 January 2025
Biotechnology
Shanghai-based Mabwell Bioscience has revealed plans to pursue a secondary listing on the Hong Kong Stock Exchange, aiming to shore up its financial position. 14 January 2025
Biotechnology
German independent biomedical research institute BioMed X has launched a new collaboration with Japanese drugmaker Daiichi Sankyo. 14 January 2025
Pharmaceutical
Chinese biopharma Hutchmed today announced that the supplemental New Drug Application for Orpathys (savolitinib) has been granted approval by the China National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alteration. 14 January 2025
Pharmaceutical
Indian contract research, development, and manufacturing organization (CRDMO) Aragen Life Sciences has received a $100 million investment from Quadria Capital. 13 January 2025
Pharmaceutical
China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication associated with bone marrow transplant, as well as a novel HIV drug that only requires two shots yearly. 13 January 2025
Biosimilars
South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, development and commercialization agreement for Epysqli (eculizumab-aagh), Samsung Bioepis’ copy of Soliris (eculizumab), in the USA. 11 January 2025
Biotechnology
US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). 10 January 2025
Pharmaceutical
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea. 10 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze